Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Neurology, Neurology, Multiple Sclerosis |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 2/6/2019 |
| Start Date: | April 2016 |
| End Date: | September 2019 |
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in
patients with relapsing forms of multiple sclerosis
patients with relapsing forms of multiple sclerosis
Inclusion Criteria:
- Diagnosis of relapsed multiple sclerosis
- Active disease
- Greater than 1 relapse in prior 2 years
Exclusion Criteria:
- Treatment with anti-CD20 monoclonal antibody within the last 12 months
- Treatment with alemtuzumab within the last 12 months
- Pregnant or nursing mothers
We found this trial at
9
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials